CHAPTER 1 INTRODUCTION
1.1 Report description
1.2 Key benefits
1.3 Research methodology
1.3.1 Secondary research
1.3.2 Primary research
1.3.3 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1 CXO perspective
CHAPTER 3 MARKET OVERVIEW
3.1 Market definition and scope
3.2 Key findings
3.2.1 Top investment pockets
3.2.2 Top winning strategies
3.3 Porters five forces analysis
3.3.1 Bargaining power of suppliers
3.3.2 Bargaining power of buyers
3.3.3 Threat of new entrants
3.3.4 Intensity of rivalry
3.3.5 Threat of substitutes
3.4 Market share analysis, 2015
3.5 Market dynamics
3.5.1 Drivers
3.5.1.1 Ageing population and increasing incidence of neurological diseases
3.5.1.2 Rise in the number of migraine and epilepsy patients and increase of neurostimulators in the treatment of depression and sleep apnea
3.5.1.3 Increasing focus of leading companies in the neurostimulation segment
3.5.1.4 New device approvals and increased clinical evidence of effectiveness
3.5.2 Restraints
3.5.2.1 Lack of skilled professionals
3.5.2.2 High cost and lack of reimbursement
3.5.3 Opportunities
3.5.3.1 Rising healthcare expenditure in developing countries
3.5.3.2 Use of neurostimulators for new indications
3.5.3.3 Rising patient awareness about nuerostimulators
CHAPTER 4 WORLD NEUROMODULATION MARKET, BY TECHNOLOGY
4.1 Overview
4.1.1 Market size and forecast
4.2 Internal neuromodulation
4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast
4.2.4 Deep brain stimulation
4.2.4.1 Market size and forecast
4.2.5 Sacral nerve stimulation
4.2.5.1 Market size and forecast
4.2.6 Spinal cord stimulation
4.2.6.1 Market size and forecast
4.2.7 Vagus nerve stimulation
4.2.7.1 Market size and forecast
4.2.8 Other neuromodulation
4.2.8.1 Market size and forecast
4.3 External Neuromodulation
4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast
4.3.4 Transcutaneous electrical nerve stimulation
4.3.4.1 Market size and forecast
4.3.5 Transcranial magnetic stimulation
4.3.5.1 Market size and forecast
CHAPTER 5 WORLD NEUROMODULATION MARKET, BY APPLICATION
5.1 Overview
5.1.1 Market size and forecast
5.2 Failed back syndrome
5.2.1 Market size and forecast
5.3 Chronic pain
5.3.1 Market size and forecast
5.4 Epilepsy
5.4.1 Market size and forecast
5.5 Essential tremor
5.5.1 Market size and forecast
5.6 Urinary and fecal incontinence
5.6.1 Market size and forecast
5.7 Depression
5.7.1 Market size and forecast
5.8 Dystonia
5.8.1 Market size and forecast
5.9 Gastroparesis
5.9.1 Market size and forecast
5.10 Parkinson's disease
5.10.1 Market size and forecast
5.11 Migraine
5.11.1 Market size and forecast
5.12 Obsessive-compulsive disorder
5.12.1 Market size and forecast
5.13 Other applications
5.13.1 Market size and forecast
CHAPTER 6 WORLD NEUROMODULATION MARKET, BY BIOMATERIAL
6.1 Overview
6.1.1 Market size and forecast
6.2 Ceramics biomaterials
6.2.1 Market size and forecast
6.3 Metallic biomaterials
6.3.1 Market size and forecast
6.4 Polymeric biomaterials
6.4.1 Market size and forecast
CHAPTER 7 WORLD NEUROMODULATION MARKET, BY GEOGRAPHY
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key market trends
7.2.2 Key growth factors and opportunities
7.2.3 Market size and forecast
7.2.3.1 U.S. market size and forecast
7.2.3.2 Canada market size and forecast
7.2.3.3 Mexico market size and forecast
7.3 Europe
7.3.1 Key market trends
7.3.2 Key growth factors and opportunities
7.3.3 Market size and forecast
7.3.3.1 Germany market size and forecast
7.3.3.2 France market size and forecast
7.3.3.3 U.K. market size and forecast
7.3.3.4 Italy market size and forecast
7.3.3.5 Spain market size and forecast
7.3.3.6 Rest of europe market size and forecast
7.4 Asia-Pacific
7.4.1 Key market trends
7.4.2 Key growth factors and opportunities
7.4.3 Market size and forecast
7.4.3.1 Japan market size and forecast
7.4.3.2 China market size and forecast
7.4.3.3 India market size and forecast
7.4.3.4 South Korea market size and forecast
7.4.3.5 Malaysia market size and forecast
7.4.3.6 Rest of Asia-Pacific market size and forecast
7.5 LAMEA
7.5.1 Key market trends
7.5.2 Key growth factors and opportunities
7.5.3 Market size and forecast
7.5.3.1 Brazil market size and forecast
7.5.3.2 Israel market size and forecast
7.5.3.3 Saudi Arabia market size and forecast
7.5.3.4 South Africa market size and forecast
7.5.3.5 Rest of LAMEA market size and forecast
CHAPTER 8 COMPANY PROFILES
8.1 Aleva Neurotherapeutics SA
8.1.1 Company overview
8.1.2 Company snapshot
8.1.3 Operating business segments
8.1.4 Key strategic moves & developments
8.2 BioControl Medical
8.2.1 Company overview
8.2.2 Company snapshot
8.2.3 Operating business segments
8.2.4 Key strategic moves & developments
8.3 Bioness Inc.
8.3.1 Company overview
8.3.2 Company snapshot
8.3.3 Operating business segments
8.3.4 Key strategic moves & developments
8.4 Boston Scientific Corporation
8.4.1 Company overview
8.4.2 Company snapshot
8.4.3 Operating business segments
8.4.4 Business performance
8.4.5 Key strategic moves & developments
8.5 EnteroMedics Inc.
8.5.1 Company overview
8.5.2 Company snapshot
8.5.3 Operating business segments
8.5.4 Business performance
8.5.5 Key strategic moves & developments
8.6 LivaNova PLC
8.6.1 Company overview
8.6.2 Company snapshot
8.6.3 Operating business segments
8.6.4 Business performance
8.6.5 Key strategic moves & developments
8.7 Medtronic plc
8.7.1 Company overview
8.7.2 Company snapshot
8.7.3 Operating business segments
8.7.4 Business performance
8.7.5 Key strategic moves & developments
8.8 NeuroPace, Inc.
8.8.1 Company overview
8.8.2 Company snapshot
8.8.3 Operating business segments
8.8.4 Key strategic moves & developments
8.9 Nevro Corporation
8.9.1 Company overview
8.9.2 Company snapshot
8.9.3 Operating business segments
8.9.4 Business performance
8.9.5 Key strategic moves & developments
8.10 St. Jude Medical, Inc.
8.10.1 Company overview
8.10.2 Company snapshot
8.10.3 Operating business segments
8.10.4 Business performance
8.10.5 Key strategic moves & developments
